Patient dies due to lack of oxygen: NHRC directs Bihar Govt to submit report in four weeks

Patna: The National Human Rights Commission (NHRC) has issued a notice to the Bihar chief secretary over the death of a heart patient allegedly due to the non-availability of oxygen cylinders at a government health centre in Munger district. 

The NHRC said it has taken suo motu cognisance of a media report of the incident that reportedly happened on December 26.    

The Commission has observed that the contents of the news report, if true, raise a serious issue of violation of human rights, which is a matter of concern.     

Also Read:NHRC notices to Delhi Chief Secretary, DCGI and Police Commissioner after epilepsy drug Sodium Valproate fails quality test

It has issued a notice to the chief secretary, calling for a detailed report within four weeks.       

The report should also include the status of the action taken against the accused as well as relief and rehabilitation provided to the next of kin of the deceased, the notice said.          

According to the media report, carried on December 28, 2023, the doctor posted at the Emergency Ward of the health centre has alleged that the oxygen cylinder for the patient was not available, while, the In-charge Medical Officer has said that there is no scarcity of the oxygen cylinders.        

Medical Dialogues team had earlier reported that the National Human Rights Commission (NHRC) had sought a complete report on the allegation of medical negligence, irregularities and poor administration at MKCG Medical College and Hospital in Odisha. The NHRC issued the reminder to the Principal Secretary, Department of Health and Family Welfare, Odisha government, District Magistrate, Berhampur and Superintendent of Police, Berhampur to file an additional report in light of the complainant’s comments, within four weeks.                                                                             

Powered by WPeMatico

Hospitals cannot admit critically ill patients in ICU without consent: GOI ICU Admission guidelines

New Delhi: The Government of India has come up with guidelines for hospitals on ICU admissions and directed that hospitals cannot admit critically ill patients in the ICU without the consent of the patient and family.

According to the latest guidelines, patients who are critically ill should not be admitted to an ICU if they do not give their consent. “Critically ill patients should not be admitted to the ICU; if Patient’s or next-of-kin informed refusal to be admitted in ICU.”

Also Read:NMC issues guidelines for assessment, rating of medical colleges from 2024-25 academic year, key takeaways

The guidelines have also mentioned that the specialist in ICU should also have specific qualifications. The Intensivist should have a postgraduate qualification in Internal Medicine, Anaesthesia, Pulmonary Medicine, Emergency Medicine, or General Surgery with either of the following

“An additional qualification in Intensive Care such as DM Critical Care/Pulmonary Critical Care, DNB/FNB Critical Care (National Board of Examinations), Certificate Courses in Critical Care of the ISCCM (IDCCM and IFCCM), Post-Doctoral Fellowship in Critical Care (PDCC/Fellowship) from an NMC recognised University, or equivalent qualifications from abroad such as the American Board Certification, Australian or New Zealand Fellowship (FANZCA or FFICANZCA), UK (CCT dual recognition), or equivalent from Canada.”

” At least one-year training in a reputed ICU abroad. A few candidates of the ISCCM Certificate Course (CTCCM) who have been certified with a 3-year training programme in Intensive Care after M.B.B.S. are also recognised as Intensivists. In addition, persons so qualified or trained must have at least two-years’ experience in ICU (at least 50% time spent in the ICU).” it said

“In case of doctors not having either of the mentioned qualifications or training, they should have extensive experience in Intensive Care in India after M.B.B.S., quantified as at least three years’ experience in ICU (at least 50% time spent in the ICU).” stated the guidelines

The new guidelines have been developed by doctors with expertise in critical care medicine working in different levels of Hospital and Intensive Care Units (ICU) across the country.

The criteria for admitting a patient to ICU should be based on organ failure and the need for organ support or in anticipation of deterioration in the medical condition.

ICU admission criteria should be based on altered level of consciousness and if a patient requires respiratory support, “Altered level of consciousness of recent onset, Hemodynamic instability (e.g., clinical features of shock, arrythmias), Need for respiratory support (e.g. escalating oxygen requirement, de-novo respiratory failure requiring non-invasive ventilation, invasive mechanical ventilation, etc.).”

“Patients with severe acute (or acute-on-chronic) illness requiring intensive monitoring and/or organ support. Any medical condition or disease with anticipation of deterioration Patients who have experienced any major intraoperative complication (e.g. cardiovascular or respiratory instability).Patients who have undergone major surgery, (e.g. thoracic, thoraco-abdominal, upper abdominal operations, trauma who require intensive monitoring or at a high risk of developing postoperative complications),” stated the guidelines.

“Any disease with a treatment limitation plan . Anyone with a living will or advanced directive against ICU care. Terminally ill patients with a medical judgement of futility. Low priority criteria in case of pandemic or disaster situation where there is resource limitation (e.g. bed, workforce, equipment).”

The ICU discharge criteria guidelines states, “return of physiological aberrations to near normal or baseline status. Reasonable resolution and stability of the acute illness that necessitated ICU admission. Patient/family agrees for ICU discharge for a treatment-limiting decision or palliative care. Based on lack of benefit from aggressive care (should be a medical decision, not obligating family agreement and as far as possible should not be based on economic constraint.”

“For infection control reasons with ensuring appropriate care of the given patient in a non ICU location. Rationing (i.e., prioritisation in the face of a resource crunch). In this event there should be an explicit and transparent written rationing policy that should be fair, consistent and reasonable.”

The minimum patient monitoring required while awaiting an ICU bed include, “Blood pressure (continuous/intermittent), Clinical monitoring (e.g., pulse rate, respiratory rate, breathing pattern, etc.) Heart rate (continuous/intermittent).Oxygen saturation – SpO2 (continuous/intermittent), Capillary refill time, Urine Output (continuous/intermittent) Neurological status e.g. Glasgow Coma Scale (GCS), Alert Verbal Pain Unresponsive (AVPU) scale etc. Intermittent temperature monitoring”

Blood sugar Minimum stabilisation required before transferring a patient to ICU includes “ensuring a secure airway (i.e., tracheal intubation if the patient has a GCS <=8) Ensuring adequate oxygenation and ventilation. Stable haemodynamics, either with or without vasoactive drug infusion. Ongoing correction of hyperglycemia/hypoglycemia and other life-threatening electrolyte/metabolic disturbances Initiation of definitive therapy for life-threatening condition (e.g., external fixation of a fractured limb, administration of antiepileptics for recurrent seizures, antiarrhythmic drug infusion for unstable arrhythmias etc, intravenous antibiotics for sepsis).”

The minimum monitoring required for transferring a critically ill patient (inter-facility transfer to hospital/ICU) includes “Blood pressure (continuous/intermittent), Clinical monitoring (pulse rate, respiratory rate, breathing pattern, etc.), Continuous Heart rate, Continuous SpO2, Neurological status (AVPU, GCS, etc.)”

Powered by WPeMatico

Kerala HC rejects 12 year old’s abortion petition

In a shocking revelation, the Kerala High Court has dismissed a plea seeking the termination of the pregnancy of a 12-year-old girl allegedly involved in an incestuous relationship with her minor brother. The court, in its December 22 order, cited the advanced stage of the pregnancy, currently at 34 weeks, and declared termination at this point as not tenable, if not impossible. Instead, the court ruled that the child must be allowed to be born through either a caesarean section or normal delivery, leaving the decision to medical experts.

For more news & updates, check out the link given below:

https://medicaldialogues.in/

Powered by WPeMatico

Cashless medical facility for Haryana Govt employees under Ayushman Bharat

Chandigarh: The Haryana government on Monday announced a cashless medical facility for government employees and their dependents on the occasion of New Year.

The state government had initiated the scheme on a pilot basis, initially covering employees from the fisheries and horticulture departments, offering cashless healthcare facilities starting November 1, 2023.

Today, the coverage has been expanded to include all regular government employees and the entire expenditure under the scheme will be borne by the state government, said an official statement.

Also Read:Cashless medical facility to be launched in Haryana on Nov 30

Implementation of this scheme is carried out through the Ayushman Bharat Haryana Health Protection Authority (State Health Authority), said the statement.

Governor Bandaru Dattatreya, in the presence of Chief Minister Manohar Lal Khattar, inaugurated the cashless healthcare facility, it said.

Dattatreya and Khattar also symbolically distributed Ayushman cards to the beneficiaries during the event here.

“All beneficiaries will greatly benefit from this scheme as the procedures listed under it will be completely cashless and the hospitals will get their claims approved from a single platform within a specified time frame. The scheme will provide more efficient, seamless, hassle-free and time-bound services to the beneficiaries and other stakeholders,” the statement said.

“The scheme not only covers six life-threatening emergencies, that is cardiac emergency, cerebral hemorrhage, coma, electric shock, third and fourth stage cancer, and any kind of accidents as per the existing provisions, but it also covers all types of indoor treatments/daycare procedures, catering to the healthcare needs.

“These services will be available to the beneficiaries in all the hospitals empanelled with Director General of Health Services under this scheme,” it said.

E-card/CCHF card will be issued to all the beneficiaries to avail benefits under the scheme. The beneficiaries can avail benefits using payee code, Aadhaar number or Parivar Pehchan Patra (family ID) number, the statement said.

Powered by WPeMatico

Healthy omega-3 fats may delay progression of deadly pulmonary fibrosis

UVA  researchers  have found in a new study that higher levels of omega-3 were associated with better lung function  and longer transplant-free survival in pulmonary fibrosis patients.

Researchers conducted  the study to  find out whether healthy fats found in nuts and fish slow the progression of potentially deadly lung scarring known as pulmonary fibrosis and delay the need for lung transplants.

UVA pulmonary researchers looked at the association between blood-plasma levels of omega-3 fatty acids-the heart-healthy fats found in foods such as salmon and flaxseeds-and the progression of pulmonary fibrosis, as well as how long patients could go without needing a transplant. The researchers found that higher levels of omega-3 were associated with better lung function and longer transplant-free survival.

While more research is needed, the researchers say their findings warrant clinical trials to determine if interventions that raise omega-3 levels could be a useful tool to improve outcomes for patients with pulmonary fibrosis and other chronic lung diseases.

“We found that higher levels of omega-3 fatty acids in the blood, which reflects several weeks of dietary intake, were linked to better lung function and longer survival,” said researcher John Kim, MD, a pulmonary and critical care expert at UVA Health and the University of Virginia School of Medicine. “Our findings suggest omega-3 fatty acids might be a targetable risk factor in pulmonary fibrosis.”

Omega-3 and Pulmonary Fibrosis

Omega-3 fatty acids have already been linked to a host of health benefits. Studies have suggested, for example, that they may lower the risk of heart disease, stroke-causing blood clots, breast cancer and other cancers, Alzheimer’s disease and dementia.

Kim and his colleagues wanted to determine if omega-3s could play a protective role in interstitial lung disease, a group of chronic lung diseases that can lead to pulmonary fibrosis. A growing problem around the world, pulmonary fibrosis is an irreversible condition that leaves the lungs unable to exchange oxygen and carbon dioxide properly. This can cause patients to become short of breath, weak, unable to exercise and a host of other symptoms. Smoking is a major risk factor.

The researchers looked at anonymized data on patients with interstitial lung disease collected in the Pulmonary Fibrosis Foundation Registry, as well as information volunteered by patients at UVA Health and the University of Chicago.

In total, the scientists reviewed information on more than 300 people with interstitial lung disease. Most were men (pulmonary fibrosis is more common in men than women), and most suffered from “idiopathic” pulmonary fibrosis, one of the conditions that fall under the banner of interstitial lung disease.

The researchers found that higher levels of omega-3 fatty acids in the blood plasma were associated with better ability to exchange carbon dioxide and longer survival without the need for a lung transplant. This did not vary much regardless of smoking history or whether the patients had cardiovascular disease.

“Higher levels of omega-3 fatty acids were predictive of better clinical outcomes in pulmonary fibrosis,” Kim said. “These findings were consistent whether you had a history of cardiovascular disease, which suggests this may be specific to pulmonary fibrosis.”

The doctors say additional research is needed to understand just how omega-3s could be having this protective benefit. They are calling for clinical trials and more mechanistic studies to obtain additional insights and determine if omega-3 fatty acid drugs or dietary changes could improve patient outcomes.

“We need further research to determine if there are specific omega-3 fatty acids that may be beneficial and, if so, what are their underlying mechanisms,” Kim said. “Similar to other chronic diseases, we hope to determine whether nutrition related interventions can have a positive impact on pulmonary fibrosis.” 

Reference:

John S. Kim, Shwu-Fan Ma, Jennie Z. Ma, Shrestha Ghosh, Krishnarao Maddipati, Imre Noth, Associations of Plasma Omega-3 Fatty Acids With Progression and Survival in Pulmonary Fibrosis, DOI:https://doi.org/10.1016/j.chest.2023.09.035.

Powered by WPeMatico

SGLT-2 inhibitors promising option for CVD prevention in diabetes patients regardless of NAFLD status: JAMA

South Korea: A recent study published in JAMA Network Open has highlighted the potential of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) as a promising option for preventing cardiovascular disease (CVD), irrespective of NAFLD status.

In the population-based cohort study, GLP-1 receptor agonists and SGLT-2 inhibitor therapy were associated with reduced risk of major adverse cardiovascular events in patients with type 2 diabetes and across baseline NAFLD status. SGLT-2i therapy was also associated with a reduced risk of hospitalization for heart failure.

Nonalcoholic fatty liver disease (NAFLD) is a cardiovascular risk factor, but it is uncertain whether glucagon-like peptide-1 receptor agonists (GLP-1RA) and SGLT2 inhibitors are associated with reduced cardiovascular risk in patients with type 2 diabetes (T2D) and concomitant NAFLD remains uncertain. Therefore, Sungho Bea, School of Pharmacy, Sungkyunkwan University, Suwon, South Korea, and colleagues aimed to investigate the outcomes of SGLT-2i and GLP-1RA therapy among T2D patients varied by the absence or presence of NAFLD.

For this purpose, the researchers performed a retrospective, population-based, nationwide cohort study using an active-comparator new-user design. Two distinct new-user active-comparator cohorts of patients aged 40 and above who initiated GLP-1 receptor agonists or SGLT2 inhibitors were propensity score-matched to patients who initiated dipeptidyl peptidase-4 inhibitors (DPP-4i).

The main outcomes were (1) major adverse cardiovascular events (MACE), a composite endpoint of hospitalization for stroke, hospitalization for myocardial infarction (MI), and cardiovascular death, and (2) hospitalization for heart failure (HHF). Cox proportional hazard models were used to estimate hazard ratios (HRs). The Wald test was applied to evaluate heterogeneity by NAFLD.

The researchers reported the following findings:

  • After 1:1 propensity score matching, 140 438 patients were retrieved in the first cohort (SGLT-2i vs DPP-4i; mean age, 57.5 years; 56.7% male) and 34 886 patients were identified in the second cohort (GLP-1RA vs DPP-4i; mean age, 59.5 years; 51.3% male).
  • Compared with DPP-4i, SGLT-2i therapy was associated with a lower risk of MACE (HR, 0.78) and HHF (HR, 0.62).
  • GLP-1RA therapy was associated with a decreased risk of MACE (HR, 0.49) but had statistically nonsignificant findings regarding HHF (HR, 0.64).
  • Stratified analysis by NAFLD status yielded consistent results for SGLT-2i (MACE with NAFLD: HR, 0.73; without NAFLD: HR, 0.81; HHF with NAFLD: HR, 0.76; without NAFLD: HR, 0.56) and for GLP-1RA (MACE with NAFLD: HR, 0.49; without NAFLD: HR, 0.49; HHF with NAFLD: HR, 0.82; without NAFLD: HR, 0.54).

“These results support the current guidelines that recommend GLP-1 receptor agonists as the first line of therapy for patients with T2D and NAFLD,” the researchers wrote.

They added, “Furthermore, this study highlights the potential of SGLT-2i as a promising option for CVD prevention regardless of NAFLD status.”

Reference:

Bea S, Jeong HE, Filion KB, et al. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status. JAMA Netw Open. 2023;6(12):e2349856. doi:10.1001/jamanetworkopen.2023.49856

Powered by WPeMatico

Graduated compression stockings demonstrate no additional benefit in preventing VTE

Venous thromboembolism or VTE, a common and severe complication of hospitalization, has a high morbidity and mortality rate, with a European epidemiological study reporting an incidence of 110 to 130 cases per 10,000 patients per year and 10% to 12% of deaths being VTE-related.

According to the ENDORSE study, 64.4% of surgical inpatients were at high risk of VTE, according to the American College of Chest Physicians criteria, compared to 41.5% of medical inpatients.

According to a recent study published in the Annals of Surgery, Benedict R.H. Turner and colleagues said that head-to-head meta-analysis and pooled trial arms show no additional benefit of GCS (graduated compression stockings) in preventing VTE and VTE-related mortality. GCS pose a risk of skin complications and economic burden. Their use is not supported for surgical inpatients based on current evidence.

This study compared VTE rates in surgical inpatients with pharmacological thromboprophylaxis and additional GCS vs. thromboprophylaxis alone.

Surgical patients have an elevated VTE risk, and recent studies question whether GCS provides extra protection against VTE compared to pharmacological thromboprophylaxis alone.

The review followed PRISMA guidelines. MEDLINE and Embase databases were searched until November 2022 for randomized trials reporting VTE rates after surgical procedures with pharmacological thromboprophylaxis, with or without GCS. The rates of DVT (deep venous thrombosis), pulmonary embolism, and VTE-related mortality were pooled through fixed and random effects.

Key findings from this investigation are:

  • The DVT risk for GCS and pharmacological thromboprophylaxis was 0.85 versus pharmacological thromboprophylaxis alone (2 studies, 70 events, 2653 participants).
  • The risk of DVT in pooled trial arms for GCS and pharmacological thromboprophylaxis was 0.54 compared to pharmacological thromboprophylaxis alone (33 trial arms, 1228 events, 14,108 participants).
  • The risk of pulmonary embolism for GCS and pharmacological prophylaxis versus pharmacological prophylaxis alone was 0.71 (27 trial arms, 32 events, 11,472 participants).
  • No between-group differences were reported in VTE-related mortality (27 trial arms, three events, 12,982 participants).

This study’s strength lies in its meta-analysis of 2 well-designed, low-bias head-to-head trials involving 2600 participants. The high-quality evidence supports the presentation of pooled DVT, PE, and VTE-related mortality rates, showing no difference between pharmacological prophylaxis and additional GCS versus pharmacological prophylaxis alone.

Reference:

Turner BRH et al. An Updated Systematic Review and Meta-analysis of the Impact of Graduated Compression Stockings in Addition to Pharmacological Thromboprophylaxis for Prevention of Venous Thromboembolism in Surgical Inpatients. Ann Surg. 2024 Jan 1;279(1):29-36.

Powered by WPeMatico

Maternal education significantly and positively linked with prenatal continuation of antidepressants

France: A recent meta-analysis published in Acta Psychiatrica Scandinavica has revealed a significant and positive association between maternal education and prenatal antidepressant continuation. However, other social determinants of health, including relationship status, race, and income, were not significantly associated with prenatal antidepressant use and continuation.

“Pregnant women having lower levels of education or high school discontinue their antidepressant medication more frequently compared to those with more years of education,” the researchers reported.

Ketevan Marr and researchers from France suggest that perinatal healthcare providers should be aware that educational level may impact antidepressant intake decision-making.

Prenatal depression is increasingly recognized as the most common morbidity in pregnancy. Its global pooled prevalence rate is estimated to be 15% and is associated with sustained poor maternal mental health in the postpartum period, and a variety of adverse short- and long-term outcomes in children.

Antidepressants are sometimes recommended for severe symptoms. Social determinants are often linked with antidepressant use in the general population, and it is unknown if this is the case for pregnant populations.

According to the study authors, no previous reviews have been conducted examining the relationship between prenatal antidepressant use and continuation and social determination. Therefore, Dr. Marr and colleagues aimed to evaluate these associations through a systematic review of the literature and meta-analyses. They provided pooled association measures between prenatal antidepressant intake and various social determinants (SD).

The researchers conducted a systematic search of five databases to identify publications from inception to October 2022 that reported associations with prenatal antidepressant intake (continuation/use) and one or more social determinants: race, education, relationship, immigration status, employment, or income. Eligible studies were included in random effects meta-analyses.

The researchers reported the following findings:

  • 23 articles describing 22 studies were included. Education was significantly and positively associated with prenatal antidepressant continuation and heterogeneity was moderate. (Odds ratio = 0.83).
  • Meta-analyses of antidepressant use and education, race, relationship status, and antidepressant continuation and income were not significant with high levels of heterogeneity.

“While most social determinants in the review were not linked with prenatal antidepressant intake, lower maternal education levels do seem to be linked with lower rates of prenatal antidepressant continuation,” the researchers wrote. “Education appears to be linked with intake of prenatal antidepressants.”

“Continued investigation into social determinants remains a research venue to disentangle the complex web of how SD and other decision-making factors interrelate during this crucial time for both expectant mothers and their offspring,” they concluded.

Reference:

Marr, K., Maguet, C., Scarlett, H., Dray-Spira, R., Dubertret, C., Gressier, F., Sutter-Dallay, L., & Melchior, M. Social determinants in prenatal antidepressant use and continuation: Systematic review and meta-analysis. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.13647

Powered by WPeMatico

EDOF intraocular lens effective and acceptable in patients with previous vitrectomy

A recent study explored the satisfaction levels of patients who underwent extended depth-of-focus (EDOF) intraocular lens (IOL) implantation following vitrectomy, shedding light on its efficacy and patient-reported outcomes in a younger demographic. This study was published in the journal Graefe’s Archive for Clinical and Experimental Ophthalmology by Willem Hoe and colleagues.

The study involved individuals aged 18 to 75 who had undergone phaco-vitrectomy or phaco after vitrectomy using the AT LARA EDOF IOL. Patients completed a questionnaire evaluating overall visual quality, near vision quality, visual disturbances, based on established survey models like Catquest, NAVQ, and APPLES.

  • Participant Demographics: Out of 89 respondents (average age 56.7 years), 53.9% received a unilateral EDOF IOL.

  • Indications for Vitrectomy: Common reasons for vitrectomy included retinal detachments, floaters, and epiretinal membranes.

  • Satisfaction Scores: The Catquest and NAVQ scores indicated high overall satisfaction, good intermediate vision, and moderate near vision.

  • Visual Disturbances: The APPLES score suggested acceptable levels of visual disturbances post EDOF IOL implantation.

  • Comparison Between Groups: No significant differences were observed in satisfaction rates between unilateral and bilateral EDOF IOL groups, except for higher spectacle dependence in the unilateral group (40% vs. 10.6%).

  • Impact of Floaters: Participants who underwent vitrectomy for floaters reported comparatively lower satisfaction rates.

  • Effect of Pre-operative Refraction: Pre-operative refraction did not impact satisfaction or visual disturbances significantly.

The study indicates that both unilateral and bilateral AT LARA EDOF IOL implantations post vitrectomy resulted in high satisfaction levels among participants. Despite a slight disparity in spectacle dependence between unilateral and bilateral groups, overall satisfaction remained comparable. This suggests that AT LARA EDOF IOLs could be a viable option for younger individuals undergoing vitrectomy, even for unilateral use.

Reference:

Van Hoe, W., Van Calster, J., Jansen, J., Vander Mijnsbrugge, J., Delbecq, A.-L., Fils, J.-F., & Stalmans, P. Patient satisfaction after EDOF intraocular lens implantation in vitrectomized eyes. Graefe s Archive for Clinical and Experimental Ophthalmology,2023;261(12):3465–3474. https://doi.org/10.1007/s00417-023-06204-z

Powered by WPeMatico

individuals with genetic predisposition to low alcohol metabolism susceptible to incident AF after alcohol consumption

In a recent study found the relationship between alcohol consumption, genetic predisposition and the risk of incident atrial fibrillation (AF). The findings of this study were published in the BMC Medicine Journal.

The study encompassed 399,329 subjects from the database of UK Biobank who were enrolled from 2006 to 2010. The study utilized genetic data to explore the  interplay between alcohol consumption and AF risk. The participants were followed until 2021 with the genetic predisposition to alcohol metabolism stratified based on polygenic risk score (PRS) tertiles.

During the median follow-up of 12.2-year, a total of 19,237 cases of AF was observed. The data revealed a significant association between genetic predisposition to alcohol metabolism and actual alcohol consumption habits (P < 0.001). Mild-to-moderate drinkers expressed a decreased risk of AF (HR 0.96, 95% CI 0.92–0.99), while heavy drinkers faced an increased risk (HR 1.06, 95% CI 1.02–1.10) compared to non-drinkers.

After stratifying the results according to PRS tertiles uncovered that mild-to-moderate drinkers had equivalent AF risks across all PRS tertiles, while the heavy drinkers expressed increased AF risk in the low PRS tertile group. In the middle/high PRS tertile groups the mild-to-moderate drinkers experienced reduced AF risks and heavy drinkers faced similar risks.

The findings highlight the critical interplay between alcohol consumption, genetic predisposition to alcohol metabolism and the risk of incident AF. The individuals with a genetic predisposition to low alcohol metabolism were observed to be more susceptible to AF by highlighting personalized risk factors for this common cardiac condition.

Source:

Park, C. S., Choi, J., Choi, J., Lee, K.-Y., Ahn, H.-J., Kwon, S., Lee, S.-R., Choi, E.-K., Kwak, S. H., & Oh, S. (2023). Risk of newly developed atrial fibrillation by alcohol consumption differs according to genetic predisposition to alcohol metabolism: a large-scale cohort study with UK Biobank. In BMC Medicine (Vol. 21, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1186/s12916-023-03229-3

Powered by WPeMatico